Internal medicine resident half day ahsan alam md
This presentation is the property of its rightful owner.
Sponsored Links
1 / 76

Acute Renal Failure PowerPoint PPT Presentation


  • 88 Views
  • Uploaded on
  • Presentation posted in: General

Internal Medicine Resident Half-Day Ahsan Alam, MD. Acute Renal Failure. Internal Medicine Resident Half-Day Ahsan Alam, MD. Acute Kidney Injury. What is Acute Kidney Injury. Abrupt decline in GFR Increase in serum creatinine P UF = (P GC - P T ) - ( p GC - p T )

Download Presentation

Acute Renal Failure

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Internal medicine resident half day ahsan alam md

Internal Medicine Resident Half-Day

Ahsan Alam, MD

Acute Renal Failure


Internal medicine resident half day ahsan alam md1

Internal Medicine Resident Half-Day

Ahsan Alam, MD

AcuteKidneyInjury


What is acute kidney injury

What is Acute Kidney Injury

Abrupt decline in GFR

Increase in serum creatinine

PUF = (PGC - PT) - (pGC - pT)

Varying definitions (RIFLE, AKIN, etc)


Rising prevalence of aki

Rising Prevalence of AKI


Acute renal failure

Why do we care about AKI?

Mortality with hospital-acquired AKI

Mortality post cardiac surgery

Nash K et al. Am J Kidney Dis 2002;39(5):930-936

Lassnigg, A. et al. J Am Soc Nephrol 2004;15:1597-1605


Case 1

Case #1

A 76 yr old female presents to ED with abdominal pain and dyspnea

Serum creatinine is 135 mmol

Does she have AKI?


Diagnostic approach

Diagnostic Approach

Time of onset – prior serum creatinine

Careful review of history and physical exam

Comorbidities

Medications

Current illness (vomiting, diarrhea, blood loss, etc)

BP, volume status, skin lesions, flank/abdominal signs


Case 11

Case #1

DM2, HTN, CAD (CABG 2004), CVA 2000 (right CEA 2009), hypothyroidism

Medications

telmistartan 80 mg, ramipril 10 mg, furosemide 40/80 mg, metoprolol, clonidine, atorvastatin, clopidogrel, insulin, thyroxine

If this is AKI, what are the most likely diagnoses?


Acute renal failure

Causes of Hospital-Acquired AKI and Mortality

4,622 consecutive patients

7.3% with AKI

Nash K et al. Am J Kidney Dis 2002;39(5):930-936


Case 12

Case #1

The patient undergoes investigations for her symptoms in hospital…


Case 13

Case #1

*CI-AKI


Case 14

Case #1

*CI-AKI

*Stage 2-3 AKI


Acute renal failure

AKI Network (AKIN) Classification

Lopes, J. A. et al. Crit Care 2008;12(4):R110


Risk factors for aki

Risk Factors for AKI

Lameire et al. NDT. 2008;6:392


Consistent risk factors

Consistent Risk Factors

  • Age

  • Hypovolemia

  • Hypotension

  • Sepsis

  • CKD

  • Hepatic dysfunction

  • Cardiac dysfunction

  • DM

  • Exposure to nephrotoxins


Differential diagnosis of aki

Differential Diagnosis of AKI

Pre-renal

Renal

Post-renal


Pre renal

Pre-renal

Hypovolemia

Diuretics, trauma, surgery, burns, hemorrhage, pancreatitis, GI loss, etc.

Decreased effective circulating volume

Nephrotic sydrome, cirrhosis, CHF, tamponade, massive PE, etc.

Renovascular obstruction

RAS/atherosclerosis/thrombosis/embolism, dissecting aneurysm, vasculitis, compression

Impaired glomerular autoregulation

NSAIDs, ACEi/ARB, calcineurin inhibitors


Intrinsic renal

Intrinsic Renal

Glomerular and small vessel diseases

Rapidly progressive GN, endocarditis, post-strep GN, vasculitides, scleroderma/malignant HTN, HUS, PET, DIC

Interstitial nephritis

Infection-related, inlammation, drug-induced, infiltrative (lymphoma, leukemia, sarcoidosis)

Tubular Lesions

Post-ishemia, nephrotoxic (drugs, contrast, anesthetics, heavy metals), pigment nephropathy, light chain, hypercalcemia


Post renal

Post-renal

Bladder flow obstruction

Urethral, bladder neck (BPH), neurogenic bladder

Ureteral obstruction (bilateral or single kidney)

Stones, clots, tumours, papillary necrosis, retroperitoneal fibrosis, surgical ligation


Urine output and aki

Urine Output and AKI

Anuric

< 50 cc / 24 hrs

Oliguric

< 500 cc / 24 hrs

Non-olguric

Normal urine output, but inadequate clearance

GFR 2 ml/min will produce ~3L of urine/day if there is no tubular reabsorption


Diagnostic approach1

Diagnostic Approach

Urine dipstick

Urine microscopy

Cellular elements

RBC, WBC, Renal tubular epithelial cells

Other (squamous, vaginal)

Casts

Hyaline, granular, waxy, RBC, WBC, tubular cell

Organisms

Bacteria, yeast

Crystals

Lipiduria

Specific gravity

pH

Leukocytes

Nitrites

Protein

Glucose

Ketones

Urobilinogen

Bilirubin

Blood


Urine findings

Urine Findings

WBC casts - pyelonephritis

WBC


Urine findings1

Urine Findings

Crystalluria – uric acid

Crystalluria – calcium oxalate

(ethylene glycol toxicity)


Urine findings2

Urine Findings

RBC casts - GN

Dysmorphic RBC - GN


Urine findings3

Urine Findings

Muddy brown casts – acute tubular necrosis


Urine findings4

Urine Findings

1.030

Specific gravity

pH

5.0

Leukocytes

Nitrites

Protein

Glucose

Ketones

+

Urobilinogen

Bilirubin

Blood

++++

80 yo female found on the floor of her apartment after 2 days, SCr 400 mol/L, K 6.8 mmol/L, CK 54,000


Urine indices

Urine Indices


Urine indices1

Urine Indices


Acute renal failure

FeNa

Limitations of FeNa

Diuretic use

Post-ischemic ATN who have less severe disease

AKI on chronic pre-renal disease (cirrhosis, CHF)

Contrast or pigment nephropathy

Acute GN or vasculitis

Alternatives

FE of urea, lithium, uric acid

FeNa = UNa/PNa x 100

UCr/PCr


Imaging

Imaging

Assess kidney size/morphology

Hydronephrosis


Kidney biopsy

Kidney Biopsy

Intrinsic renal AKI

Indications

Isolated glomerular hematuria with proteinuria

Nephrotic syndrome

Acute nephritic syndrome

Unexplained acute or rapidly progressive AKI


Kidney biopsy1

Kidney Biopsy

Crescentic GN


Principles of aki management

Principles of AKI Management

  • Identify AKI

  • Avoid further nephrotoxic injury

  • Optimize renal hemodynamics

  • Treat complications

    • Fluid balance, electrolytes, uremia

  • Nutritional support

  • Renal Support (RRT)

  • Monitoring after AKI


Medications

Medications

  • Pre-renal

    • Calcineurin inhibitors, radiocontrast, ACEi/ ARB, NSAIDS, amphotericin B

  • Intra-renal

    • aminoglycosides, amphotericin B, cisplatin, cephalosporins, sulfa, rifampin, NSAIDS, interferon

  • Post-renal

    • acyclovir, MTX, indinavir, sulfadiazine

  • Review renal dosing of medications


Fluid management

Fluid Management

  • Correct fluid deficit

    • Will not guarantee AKI prevention

    • Studies of PA catheters did not reduce AKI

  • High urine flow in specific conditions

    • Myoglobinuria, tumour lysis, contrast media, etc.

  • Little evidence on fluid choice

    • Crystalloids

    • Hypooncotic colloids (4% albumin)

    • Hyperoncotic solutions (HES, dextrans) carry risk of renal dysfunction


Renal perfusion and vasoactive agents

Renal Perfusion and Vasoactive Agents

  • No support for

    • Loop diuretics

    • Dopamine

  • Selected use of

    • Mannitol (Rhabdomyolysis, post-cardiac surgery)

  • Unclear support for

    • Natriuretic peptides (ANP, BNP)

    • Fenoldopam (DA agonist)

    • Theophylline (adenosine antagonist)


Renal perfusion

Renal Perfusion

  • Vasopressors

  • Inotropes to improve low cardiac function

  • Target MAP needs to be individualized

    • Commonly 65 mmHg

    • Higher in elderly where autoregulation impaired


Nutrition in aki

Nutrition in AKI

  • AKI is a catabolic state

    • Inadequate nutritional support can delay renal recovery

  • Cochrane review 2010:

    • “There is not enough evidence to support the effectiveness of nutritional support for AKI…”

  • Adequate calorie delivery in anuric patient will necessitate RRT


Treat complications

Treat Complications

  • Monitor and correct electrolytes, acidosis

  • Renal replacement therapy

    • If indicated, do not withhold until patient is anuric


Indications for dialysis

Indications for Dialysis

A E I O U

Acidosis

Electrolyte disturbance

Ingestions

Overload (volume)

Uremia


New paradigm for aki

New Paradigm for AKI

CKD

AKD

AKI


Natural history of aki

Natural history of AKI

Cerda et al. cJASN. 2008;


Follow up after aki

Follow up after AKI


Questions

Questions?


Case 15

Case #1

*CI-AKI

*Stage 2-3 AKI


Fluids isotonic vs hypotonic

Fluids – Isotonic vs. Hypotonic

Isotonic saline (0.9%) more protective than half normal (0.45%)

1,620 pts undergoing cardiac catheterization

Goal is to achieve ‘good’ urine flow

Mueller C et al. Arch Intern Med. 162: 329-336, 2002


Fluids

Fluids

Optimal rate and duration is not clear

IV rate >1-1.5 ml/kg/hr to achieve urine flow >150 ml/hr

At least 1hr (3-12hr) prior and 3-6hr (6-12hr) after contrast


Acute renal failure

Bicarbonate vs Saline

Zoungas S et al. Ann Intern Med 2009;151:631-638


Acute renal failure

Bicarbonate vs Saline

Zoungas S et al. Ann Intern Med 2009;151:631-638


Acute renal failure

Bicarbonate vs Saline – Adverse Events

Dialysis

(15/1552)

Mortality

CHF

Zoungas S et al. Ann Intern Med 2009;151:631-638


Bicarbonate

Bicarbonate

Effectiveness is uncertain

Evidence that it should be preferred over isotonic saline is weak and inconsistent


N acetylcysteine rationale

N-Acetylcysteine – Rationale

Scavenger of free radicals

Vasodilatory properties; enhanced NO availability

Attenuates ischemic injury in animals


N acetylcysteine

N-Acetylcysteine

Kelly AM et al. Ann Intern Med 2008;148:284-294


Standard vs high dose nac

Standard vs. High Dose NAC

N=354, <12h post STEMI

Standard: 600 mg IV pre, 600 mg PO bid post

High: 1200 mg IV pre, 1200 mg PO bid post

In-hopsital mortality:11% placebo 4% low-dose3% high dose

Marenzi G et al. N Engl J Med 2006;354:2773-2782


N acetylcysteine1

N-Acetylcysteine

Actual benefit is debatable, but safe* and inexpensive

Appropriate to give IV or high-dose oral

Give in combination with IV isotonic fluids


Contrast medium

Contrast Medium

Limit ‘volume’ of iodine

Iso-osmolar or low-osmolar contrast preferred

IA: iso-osmolar

IV: low or iso-osmolar

grams iodine/GFR < 1


Muhc ct contrast

MUHC CT Contrast

Iohexol (Omnipaque)

Low-osmolar; Omni 300 ~ 650 mOsm/kg

Iodixanol (Visipaque)

Iso-osmolar; Visi270 or 320 ~ 290 mOsm/kg

Both non-ionic

Concentration from 140-400 mg iodine/ml


Hemodialysis hemofiltration

Hemodialysis/Hemofiltration

5 trials with conflicting results

RR for AKI 1.35 (95%CI 0.93-1.94)

Insufficient evidence to recommend prophylactic hemodialysis or hemofiltration


Case 2

Case #2

58M with EtOH cirrhosis, admitted for SBP

4 months ago creatinine 68 , now 220

What may be the cause of his kidney dysfunction, and how would you manage?


Acute renal failure

HRS

Chronic or acute liver disease with advanced hepatic failure and portal hypertension

SCr > 133 mg/dl or 24-hr CrCl < 40 ml/min

No improvement in SCr after diuretic withdrawal and plasma volume expansion (saline 1.5 L) +/- with albumin (1 g/kg to max of 100 g/day)

No nephrotoxin, shock, infection, GI loss

No parenchymal renal disease (no proteinuria microhematuria and/or abnormal US)

Minor diagnostic criteria

Urine volume < 500 mL/d

UNa < 10 mEq/L

UOsm > POsm

Urine RBC < 50/hpf

Serum Na < 130 mEq/L


Treatment to reverse hrs

Treatment to Reverse HRS

Which of the following have been shown to be effective?

Albumin

Combination Midodrine and Octreotide

Noradrenaline

Terlipressin

Dopamine


Albumin

Albumin

Intravenous albumin in addition to antibiotics improves survival in SBP

Sort et al. NEJM 1999;341:403

Albumin indicated when doing paracentesis

Improved outcomes when combined with pressors


Midodrine and octreotide

Midodrine and Octreotide

Octreotide 100 ug sq TID increasing to 200 ug sq TID

inhibitor of endogenous vasodilators and glucagon

Midodrine 7.5 mg po TID increasing to 12.5 mg po TID

peripheral vasoconstriction

Midodrine and Octreotide sometimes helpful

Response rate about 30-50%


Noradrenalin

Noradrenalin

Effects of Noradrenalin and albumin in patients with Type I HRS: A Pilot Study. Hepatology 2002; 36:374

Noradrenaline started at 0.1 ug/kg/min and increased every 4 hrs based on BP by 0.05 ug/kg/min to max of 0.7 ug/kg/min

Combined treatment lowered creatinine from 2.6 to 1.6 over 10 days

Overall 2-month survival in this group of 12 patients was 58%


Terlipressin

Terlipressin

Numerous studies have shown a benefit in treating patients with HRS benefit is generally a 50% improvement in GFR.

Better when combined with albumin

Ischemic complications and worsening of cerebral hyperemia

Effect is not long lasting


Terlipressin and change in serum creatinine

Terlipressin and Change in Serum Creatinine


Case 3

Case 3

68 year old female admitted with worsening dyspnea, leg edema

Known CAD, CHF (LVEF 10%), DM2, CKD (Cr 140), …

Meds: ACEi, BB, nitrate, loop diuretic, aldactone, statin, ASA, insulin, etc.

Aggressively diuresed for 3 days, Cr 250


Cardio renal conundrum

Cardio-Renal Conundrum


Cardiorenal syndrome

Cardiorenal syndrome


Crs type 1

CRS Type 1


Crs type 2

CRS Type 2


Crs type 3

CRS Type 3


Crs type 4

CRS Type 4


Crs type 5

CRS Type 5


Cardio renal syndrome

Cardio-Renal Syndrome

AT blockade interferes with autoregulation and may need to be held if GFR deteriorates

Avoidance of agents which interfere with renal sodium handling

NSAIDs, Coxibs, Thiazolidinediones

Nephrotoxic agents (e.g. contrast)

Serum potassium may also limit continued use of RAS blockade or K-sparing diuretics


  • Login